Clinical Trials
71 trialsT Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
M.D. Anderson Cancer Center
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
SELECT-2CAR
Beijing Biotech
BRIA-ABC
BriaCell Therapeutics Corporation
DUAL-NK-BC
Beijing Biotech
DUAL-NK-PDAC
Beijing Biotech
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
PNeoVCA
Mayo Clinic
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
SELECT-CAR-NK
Essen Biotech
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Fred Hutchinson Cancer Center
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Triple-B
The Netherlands Cancer Institute
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
NYM
Jonsson Comprehensive Cancer Center
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Acepodia Biotech, Inc.
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
Peking University
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
MODULATE
Immodulon Therapeutics Ltd
Immunotherapy for the Treatment of Advanced Solid Tumor
Tongji Hospital
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
METEORA-II
ETOP IBCSG Partners Foundation
Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients
Capital Medical University
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
NexImmune Inc.
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
Albert Einstein College of Medicine
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
TONIC
The Netherlands Cancer Institute
CHEMOIMMUNE
Centre Leon Berard
NY-ESO-1
GlaxoSmithKline
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
i-GO
UMC Utrecht
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
National Institutes of Health Clinical Center (CC)
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
University Health Network, Toronto
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)